Cambridge Healthtech Institute’s 6th Annual

Immunomodulatory Therapeutic Antibodies for Cancer

Emerging Targets, Combinations, and Antibody Engineering for Next-Generation Immunotherapy

August 27-28, 2018

Despite the success of immunomodulatory antibodies in immuno-oncology, challenges remain in expanding the target space, engineering next-generation antibodies with improved efficacy and safety, and addressing innate and acquired resistance to immunotherapy. CHI’s Sixth Annual Immunomodulatory Therapeutic Antibodies for Cancer meeting will explore next-generation immunotherapies, emerging targets and combinations, and strategies for overcoming resistance. It will provide case studies of antibody development in immuno-oncology from preclinical to clinical development.

Coverage will include, but is not limited to:

  • Emerging targets and pathways for immunomodulatory antibodies
  • Strategies to improve therapeutic efficacy and safety of novel biologics
  • Novel immunotherapies and combinations
  • Therapeutic strategies for non-responders and mechanism of resistance
  • Antibody engineering for immunotherapy
  • Case studies in clinical immuno-oncology programs

If you would like to submit a proposal to give a presentation at this meeting, please click here.

The deadline for priority consideration is February 9, 2018.

All proposals are subject to review by session chairmen and/or the Scientific Advisory Committee to ensure the overall quality of the conference program. Additionally, as per Cambridge Healthtech Institute policy, a select number of vendors and consultants who provide products and services will be offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships.

For more details on the conference, please contact:
Julia Boguslavsky
Executive Director, Conferences
Cambridge Healthtech Institute

For partnering and sponsorship information, please contact:
Rod Eymael
Manager, Business Development
Cambridge Healthtech Institute
Phone: (+1) 781-247-6286